Erdafitinib (Janssen Research and Development).
The anticipated launch of targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma shall push the growth of the BTC market size in the offing.
Further, an increase in the BTC incidence, increment in healthcare spending, extensive R&D along better awareness of cancer is expected to give the BTC market size growth a much-needed momentum.
Get in touch for a holistic view of the
The BTC market report also covers the market of Cholangiocarcinoma including (Intrahepatic and Extrahepatic), Gallbladder, treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market s underlying potential, and plans strategically to tackle market risks.